Gabapentin
Product Images NDC 50090-3353

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-3353). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Gabapentin Capsules Usp 1)

A mathematical formula calculating creatinine clearance (CLCr) based on patient age, weight, serum creatinine level, and a gender adjustment factor. This formula includes age in years, weight in kilograms, serum creatinine in mg/dL, and multiplies by 0.85 for female patients.*

FDA Label Image

Chem Structure (Gabapentin Capsules Usp 2)

Chemical structure of gabapentin showing its cyclohexyl group attached to an amino and a carboxylic acid functional group.*

FDA Label Image

10 (Gabapentin Capsules Usp 3)

A line graph depicting mean pain scores over an 8-week period for Gabapentin 3600 mg/day versus placebo. The x-axis represents weeks, with a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows the mean pain score, illustrating a decrease in pain for the Gabapentin group compared to the placebo group.*

FDA Label Image

10 (Gabapentin Capsules Usp 4)

Line graph depicting mean pain scores over a 7-week period, comparing placebo and two dosages of Gabapentin (1800 mg/day and 2400 mg/day). The x-axis shows weeks including baseline, and the y-axis shows mean pain score values from 0 to 10. The graph indicates changes during a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

10 (Gabapentin Capsules Usp 5)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) doses in two studies. Study 1 shows PBO at 12% and GBP 3600 at 29%. Study 2 shows PBO at 14%, GBP 1800 at 32%, and GBP 2400 at 34%. Statistical significance is indicated (p < 0.01 and p < 0.001).*

FDA Label Image

Figure 4 (Gabapentin Capsules Usp 6)

A scatter plot showing the percentage difference versus daily dose (mg) for Gabapentin across three studies labeled 'a', 'b', and 'c'. The graph displays data points for doses approximately 600 mg to 1800 mg on the x-axis and percentage difference from about 2% to 22% on the y-axis, with distinct markers for each study.*

FDA Label Image

Label Image (Lbl500903353)

Gabapentin 300 mg capsules label from A-S Medication Solutions, product NDC 50090-3353, product number 9017-0. The label includes storage instructions to keep between 68 and 77 degrees Fahrenheit and specifies a package size of 33 capsules. It also mentions the manufacturer as Amneal Pharmaceuticals and includes distribution details with a QR code and lot number area.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.